Biotechnology

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases and other public health threats. The company leverages four technology platforms—antibody, T-cell, innate immunity, and siRNA—to develop a robust pipeline of candidates targeting hepatitis B, hepatitis D, influenza A, and HIV. Vir gained significant prominence for its development of sotrovimab, a monoclonal antibody for COVID-19, in partnership with GSK. Headquartered in San Francisco, the company continues to advance multiple late-stage clinical programs, including combination therapies for chronic hepatitis B and D, while expanding its oncology footprint through masked T-cell engager technologies.